UAE says China’s Sinofarm vaccine has 86% effectiveness against Kovid-19


The health ministry said the vaccine results were based on an interim analysis of late-stage clinical trials, which the UAE launched in July, according to a statement by the state news agency.

Although few details were provided, the statement marked the first publicly published information on the effectiveness of the Chinese vaccine, developed by Sinofarm’s unit, China National Biotech Group (CNBG). The UAE approved emergency use for frontline workers in September.

The analysis did not reveal any serious safety concerns, although it did not specify whether individual participants were subjected to any special side effects, or how many volunteers were vaccinated or given placebo, the statement said.

The statement added that the “official registration” of the Kovid-19 vaccine was “a major step towards combating the global epidemic.” The statement did not provide any details on what will apply to the official registration.

The clinical trial involved 31,000 volunteers from 125 nationalities in the UAE, the statement said. As part of the voluntary program, about 100,000 people in the emirate have also been vaccinated, Jamal al-Kabi, a senior health official in the UAE, told CNN.

Vice President and Prime Minister of the UAE Sheikh Mohammed bin Rashid Al Maktoum Was in the picture Received Jab during trial in November.

CNN Synoform has reached out for more details.

In a photo published by the Xinhua News Agency on April 11, 2020, staff members inspect and clean equipment at a vaccine manufacturing plant in Beijing's Sinofarm.
China currently has five coronavirus candidates from four companies that have reached Phase 3 clinical trials, the last and most important step of testing before seeking regulatory approval.
After largely eradicating the spread of coronavirus within its borders, Chinese drug manufacturers had to look abroad for locations to test the effectiveness of their vaccines. Together, they have launched Phase 3 trials in at least 16 countries.

In turn, many host countries are promised early access to successful vaccines – and in some cases, technology knows how to make them locally.

The UAE company, in partnership with Synopharm, has previously said it expects to make 75 to 100 million doses next year.

In November, Sinofarm chairman Liu Jingzhen said dozens of countries had requested the company to buy the vaccine. He did not name the countries or elaborate on the dosage they suggested, but said CNBG was capable of producing more than a billion doses in 2021.

Huang said China not only has the political will (for its vaccine diplomacy), but also a strong ability to be.

Compared to Pfizer and Moderna, most Chinese vaccines do not require a cooling temperature for storage, making transportation and distribution much easier, especially in developing countries that lack cold storage capacity.

The Pfizer vaccine has been approved for use by the United Kingdom, which began vaccinating people this week, while the moderns are still in the final stages in many countries.

Both Pfizer and Moderna vaccines use fragments of a genetic material called messenger RNA (mRNA) to create artificial fragments of coronavirus in the body and stimulate the immune response – a new technology not used in existing vaccines.

But mRNA is sensitive to degradation at room temperature. The Moderna vaccine must be stored at -20 સે C (-4 ફેર F) or refrigerator temperature for 30 days, while the Pfizer vaccine must be stored at -75˚C (-103). ˚F), and used in refrigeration at high temperatures once within five days.

SynoPharm, meanwhile, uses a long-running approach that has proven effective in other vaccines such as polio and flu shots. Their coronavirus vaccines use inactivated whole viruses to help the body develop immunity, and only need to be stored at a standard refrigerator temperature of 2˚C to 8˚C (36˚F to 46˚F). The other Chinese vaccines in the product can be kept at the same temperature.

Contributed by CNN’s Beijing Bureau in Hong Kong and Amrut Gan.

.